Biosignatures is a highly innovative software based diagnostics company generating novel diagnostic products.

The company has developed a sophisticated, patented software system which it is using to create diagnostics from the analysis of patient blood samples. This technology has the potential to replace the existing diagnostic techniques used for diseases like Alzheimer’s, thyroid cancer and prostate cancer with simple blood tests.

This is possible because Biosignatures’ technology has achieved the elusive goal of enabling the science of proteomics to deliver on its immense potential. As proof of this claim, the company now has a portfolio of products with proven performance in Phase 2 blind tests.

The products are blood based diagnostic tests processed using a combination of proteomic separation and Biosignatures’ unique analysis software technology. All the products under development offer significant costs savings to health service payors, with many also bringing major improvements to the patient experience by reducing the need for current more invasive practice.

Biosignatures is addressing opportunities in the diagnostics market by deploying a powerful patented platform technology for advanced statistical analysis and classification of protein separation patterns (the Tiger platform). This unique, proven proteomics technology, invented, incubated and tested working with industry leaders such as Novartis and AstraZeneca, will be combined with world-leading expertise in proteomics experiment and study design, to cost-effectively and rapidly discover and develop new, patentable diagnostics, in the form of patterns of proteins, "biosignatures".